[1] 郑一敏,刘晶晶,胥秀英,等.慢性髓性白血病发病机制及药物研究进展[J].重庆理工大学学报(自然科学), 2021, 35(9): 204-213. [2] JABBOUR E, KANTARJIAN H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring[J]. Am J Hematol, 2020, 95(6): 691-709. DOI: 10.1002/ajh.25792. [3] 马嘉鑫,刘永忠,李文宏,等.中药逆转白血病多药耐药机制研究进展[J].江西中医药大学学报, 2022, 34(4): 120-124. [4] 席婕,刘晖.人参皂苷Rg1对鼻咽癌CNE-2细胞凋亡、侵袭和迁移的影响[J].临床误诊误治, 2018, 31(12): 99-104. DOI: 10.3969/j.issn.1002-3429.2018.12.025. [5] LI J, WEI Q, ZUO G W, et al. Ginsenoside Rg1 induces apoptosis through inhibition of the EpoR-mediated JAK2/STAT5 signalling pathway in the TF-1/Epo human leukemia cell line[J]. Asian Pac J Cancer Prev, 2014, 15(6): 2453-2459. DOI: 10.7314/apjcp.2014.15.6.2453. [6] 吕丽娜,姜丽红.人参皂苷Rg1对心血管系统的药理作用研究进展[J].现代中药研究与实践, 2020, 34(6): 83-86. DOI: 10.13728/j.1673-6427.2020.06.018. [7] 李贵明,李燕.人参皂苷药理作用研究现状[J].中国临床药理学杂志, 2020, 36(8): 1024-1027. DOI: 10.13699/j.cnki.1001-6821.2020.08.024. [8] 张进,王顺和,汪兰,等.人参皂苷Rg1通过AMPK/mTOR信号通路调控自噬延缓小鼠脑衰老的研究[J].中国药理学通报, 2022, 38(7): 987-993. DOI: 10.12360/CPB202110092. [9] 韩艳军,王翠丽,刘小虎,等.人参皂苷Rg1对K562细胞增殖的影响[J].大理大学学报, 2020, 5(4):16-20. DOI: 10.3969/j.issn.2096-2266.2020.04.004. [10] 韩艳军,周玥.人参皂苷Rg1诱导白血病K562细胞老化的研究[J].医学研究生学报, 2020, 33(1): 32-37. DOI: 10.16571/j.cnki.1008-8199.2020.01.006. [11] HAFERLACH T, SCHMIDTS I. The power and potential of integrated diagnostics in acute myeloid leukaemia[J]. Br J Haematol, 2020, 188(1): 36-48. DOI: 10.1111/bjh.16360. [12] KANTARJIAN H M, KEATING M J, FREIREICH E J. Toward the potential cure of leukemias in the next decade[J]. Cancer, 2018, 124(22): 4301-4313. DOI: 10.1002/cncr.31669. [13] HIDA K, AKIYAMA K, OHGA N, et al. Tumour endothelial cells acquire drug resistance in a tumour microenvironment[J]. J Biochem, 2013, 153(3): 243-249. DOI: 10.1093/jb/mvs152. [14] 刘亚鑫,魏雪娇,黄惠铭,等.中药诱导细胞周期阻滞抗肿瘤研究进展[J].中国实验方剂学杂志, 2023, 29(2): 222-234. DOI: 10.13422/j.cnki.syfjx.202201821. [15] EVAN G I, VOUSDEN K H. Proliferation, cell cycle and apoptosis in cancer[J]. Nature, 2001, 411(6835):342-348.DOI: 10.1038/35077213. [16] WENZEL E S, SINGH A T K. Cell-cycle checkpoints and aneuploidy on the path to cancer[J]. In Vivo, 2018, 32(1): 1-5. DOI: 10.21873/invivo.11197. |